齐拉西酮联用奥氮平对精神分裂症疗效及糖化血红蛋白的影响

Abstract
Figure/Table
References (0)
Related Citation (10)

Download: PDF (2060 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the efficacy of ziprasidone and olanzapine in treating patients with schizophrenia and their influences on blood glucose and glycosylated hemoglobin at early stage of course of treatment. Methods: 197 cases of schizophrenia patients were randomly divided into experimantal group (99 cases administered only with ziprasidone) and control group (98 cases administered with ziprasidone and olanzapin). All the patients were selected from 7 different psychiatric hospital who were diagnosed from 2013.1-2014.1. Both groups were administered with olanzapin and olanzapine at the first 5 weeks. Then olanzapine was abandoned gradually in experimental group, while the control group went on its original treatment both groups were treated for 12 weeks. Scores of PANSS, level of blood glucose and glycosylated hemoglobin were compared between the two groups before treatment and the 1st, 5st, 7st, 9st, 12st weekend after treatment. Results: Both groups showed significant decrease after the treatment (P<0.05), but there’s no statistical difference at every time point (P>0.05). The level of limosis blood glucose in control group was higher than that in experimental group at the 9th and 12th weekend (P<0.05). There’s no statistical difference at the level of glycosylated hemoglobin in both groups by every time point (P>0.05). Conclusion: The efficacy of single ziprasidone and combination treatment is similar, but single ziprasidone at later stage shows more benefit for blood glucose control and meanwhile shows relatively reliable efficacy.

Key words： schizophrenia ziprasidone olanzapine metabolic syndrome glycosylated hemoglobin

Received: 05 March 2015

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Yong1
	2
	HUANG Hanjin2
	TANG Jianliang3.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2015/V45/I9/674

[1] Chwieduk CM, Keating GM. Paliperidone extended release:A review of its use in the management of schizophrenia[J]. Drugs, 2010, 70(10): 1295-1317.
[2] 方泽忠, 连国民. 五种非典型抗精神病药物对血糖及血脂水平影响的对照研究[J]. 浙江临床医学, 2008, 10(3): 319-320.
[3] Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel anti-psychotics and new onset diabetes[J]. Biol Psychiatry, 1998, 44(8): 778-783.
[4] 罗诚, 杨俊伟, 任继平. 奥氮平对精神分裂症患者血脂、体质量的影响研究[J]. 精神医学杂志, 2008, 21(1): 46-47.
[5] Karayal ON, Glue P, Bachinsky M, et al. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder[J]. J Psychiatr Pract, 2011, 17(2):100-109.
[6] Baptista T, Serrano A, Uzcátegui E, et al. The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela[J]. Schizophr Res, 2011, 126(1-3): 93-102.
[7] 徐爱良, 金燕君, 蔡文治. 精神分裂症患者药物治疗后血糖、血脂和尿酸代谢变化及相关因素分析[J]. 温州医学院学报, 2013, 43(5): 340-342.
[8] Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind muhicenter comparison ot the efficacy and tolerability of ziprasidone and olanzapine in acutely ill in patients with schizophrenia or schizoaffective disorder[J].Am J Psychiatry, 2004, 161(10): 1837-1847.
[9] Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding propreties and real-world psychiatric practice[J]. J Clin Psychiatry, 2003, 64 Suppl 19: 6-12.
[10] Caley CF, Cooper CK.Ziprasidone: the fifth atypical antipsychotic[J]. Ann Phannacother, 2002, 36(5): 839-851.
[11] 刘洁, 张卫星. 糖化血红蛋白检测在2型糖尿病患者中的应用与分析[J].中国医药指南, 2014, 12(1): 22-23.
[12] Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics[J]. Diabetes Metab,2007, 33 (3): 169-175.
[13] Zhang Y, Dai G. Efficacy and metabolic influence of paliperi done ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China [J]. Hum Psychopharmacol, 2012, 27(6): 605-614.